This phase II trial tests how well telisotuzumab vedotin and osimertinib works for the treatment of non small cell lung cancer that is growing, spreading, or getting worse (progressive) and for which no treatment is currently available (incurable). Telisotuzumab vedotin is a monoclonal antibody, called telisotuzumab, linked to a toxic agent, called vedotin. Telisotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as c-Met receptors, and delivers vedotin to kill them. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving telisotuzumab vedotin and osimertinib may be effective for treating progressive, incurable non small cell lung cancer.

Start Date19 Feb 2026

Sponsor / Collaborator

Jonsson Comprehensive Cancer Center

[+1]

NCT06568939

/ RecruitingPhase 2

A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed.
Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 70 to 80 sites worldwide.
Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Start Date20 Jan 2025

Sponsor / Collaborator

AbbVie, Inc.

NCT06093503

/ WithdrawnPhase 3

Phase 3, Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Combined With Osimertinib vs Platinum-Based Chemotherapy in Subjects With c-Met Overexpressing (OE) EGFR Mutant, Locally Advanced/Metastatic Non-Squamous NSCLC After a First Progression on Prior Third Generation EGFR TKi Treatment

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how telisotuzumab vedotin in combination with osimertinib affects the disease state compared to standard of care in adult participants with locally advanced/metastatic non-squamous NSCLC that has a mutation in the epidermal growth factor receptor (EGFR) gene and that overexpresses the c-Met protein. Change in disease activity will be assessed.
Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC that overexpresses the c-Met protein. Participants are randomly placed in one of the two groups to receive telisotuzumab vedotin and osimertinib or standard of care chemotherapy. Approximately 250 adult participants with locally advanced/metastatic non-squamous NSCLC that has a mutation in the EGFR gene and that overexpresses the c-Met protein will be enrolled in the study in approximately 180 sites worldwide.
Participants will receive intravenous telisotuzumab vedotin every 2 weeks in combination with oral osimertinib tablets daily or standard of care chemotherapy (carboplatin/pemetrexed or cisplatin/pemetrexed as prescribed by the physician). Overall duration of the study is estimated to be approximately 47 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Start Date31 May 2024

Sponsor / Collaborator

AbbVie, Inc.

100 Clinical Results associated with Telisotuzumab vedotin

100 Translational Medicine associated with Telisotuzumab vedotin

100 Patents (Medical) associated with Telisotuzumab vedotin

584

Literatures (Medical) associated with Telisotuzumab vedotin

01 Mar 2026·CPT-Pharmacometrics & Systems Pharmacology

Population Pharmacokinetics and Exposure‐Response Analyses for Telisotuzumab Vedotin in Patients With c‐Met Protein Overexpressing Tumors

Article

Author: Parikh, Apurvasena ; Brunsdon, Priya ; Ratajczak, Christine ; Schmitt, Vanessa ; Menon, Rajeev M. ; Engelhardt, Benjamin ; Babel, Heiko ; Mensing, Sven

ABSTRACT:

Telisotuzumab vedotin (Teliso‐V) is a c‐Met‐directed antibody‐drug conjugate that delivers a cytotoxic microtubule inhibitor monomethyl auristatin E (MMAE) payload to c‐Met‐expressing tumor cells. It received accelerated approval from the US FDA for the treatment of adults with locally advanced or metastatic non‐squamous non‐small cell lung cancer (NSCLC) with high c‐Met protein overexpression (≥ 50% of tumor cells with strong [3+] staining) at a dose of 1.9 mg/kg every 2 weeks (Q2W; maximum 190 mg for patients ≥ 100 kg) as an intravenous infusion. Population pharmacokinetic (PK) modeling used pooled data from a phase 1 ( N = 35) and phase 2 study ( N = 269) to describe the Teliso‐V conjugate and unconjugated MMAE PK and evaluate the impact of intrinsic and extrinsic factors on exposures in patients with solid tumors. Body weight, race, albumin, and anti‐drug antibody status were identified as significant covariates on Teliso‐V conjugate clearance, but did not result in clinically meaningful changes in exposure. The exposure‐response evaluations for efficacy (based on the pivotal phase 2 study) showed significant correlations between conjugate exposure and overall response rates. Higher conjugate exposures were also correlated with improved progression‐free survival and overall survival, demonstrating meaningful clinical benefit with the 1.9 mg/kg Q2W dosing regimen. Exposure‐safety evaluations showed significant relationships between conjugate exposures and grade ≥ 2 and grade ≥ 3 peripheral neuropathy, and grade ≥ 2 corneal epitheliopathy. Unconjugated MMAE payload exposures were correlated with a greater probability of grade ≥ 3 treatment‐emergent adverse events. The 1.9 mg/kg Q2W dose maximized efficacy while balancing adverse events in patients with c‐Met overexpressing NSCLC.

31 Dec 2025·mAbs

Antibodies to watch in 2025

Review

Author: Kapoor, Vaishali ; Kaplon, Hélène ; Crescioli, Silvia ; Visweswaraiah, Jyothsna ; Reichert, Janice M. ; Wang, Lin

The commercial development of antibody therapeutics is a global enterprise involving thousands of biopharmaceutical firms and supporting service organizations. To date, their combined efforts have resulted in over 200 marketed antibody therapeutics and a pipeline of nearly 1,400 investigational product candidates that are undergoing evaluation in clinical studies as treatments for a wide variety of diseases. Here, we discuss key events in antibody therapeutics development that occurred during 2024 and forecast key events related to the late-stage clinical pipeline that may occur in 2025. In particular, we report on 21 antibody therapeutics granted a first approval in at least one country or region during 2024, including bispecific antibodies tarlatamab (IMDELLTRA®), zanidatamab (Ziihera®), zenocutuzumab (BIZENGRI®), odronextamab (Ordspono®), ivonescimab (®), and antibody-drug conjugate (ADC) sacituzumab tirumotecan (®). We also discuss 30 investigational antibody therapeutics for which marketing applications were undergoing review by at least one regulatory agency, as of our last update on December 9, 2024, including ADCs datopotamab deruxtecan, telisotuzumab vedotin, patritumab deruxtecan, trastuzumab botidotin, becotatug vedotin, and trastuzumab rezetecan. Of 178 antibody therapeutics we include in the late-stage pipeline, we summarize key data for 18 for which marketing applications may be submitted by the end of 2025, such as bi- or multispecific antibodies denecimig, sonelokimab, erfonrilimab, and anbenitamab. Key trends in the development and approval of antibody formats such as bispecifics and ADCs, as well as clinical-phase transition and global approval success rates for these antibody formats, are reported.

31 Dec 2025·mAbs

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity

Article

Author: Gesner, Thomas ; Logel, Claude ; Xie, Kathleen T. ; Cebe, Regis ; Wu, Nila C. ; Li, Xun ; Shi, Xingyi ; Simmons, Quincey ; Velazquez, Roberto ; Tschantz, William R. ; Sagar, Vivek ; Hainzl, Dominik ; Korn, Joshua ; Barzaghi-Rinaudo, Patrizia ; Malamas, Anthony ; Mercan, Samuele ; Green, Andrew ; McLaughlin, Margaret ; Huber, Thomas ; Mueller, Kathrin ; D’Alessio, Joseph A. ; Synan, Alyssa

P-cadherin (pCAD) and LI-cadherin (CDH17) are cell-surface proteins belonging to the cadherin superfamily that are both highly expressed in colorectal cancer. This co-expression profile presents a novel and attractive opportunity for a dual targeting approach using an antibody-drug conjugate (ADC). In this study, we used a unique avidity-driven in vitro screening approach to generate pCAD x CDH17 bispecific antibodies that selectively target cells expressing both antigens over cells expressing only pCAD or only CDH17. Based on in vitro binding and inhibition of cell proliferation results, we selected a lead bispecific antibody to link to the cytotoxic payload monomethyl auristatin E (MMAE) to generate a pCAD x CDH17 bispecific MMAE ADC. In in vivo dual flank mouse models, we demonstrated antitumor activity of the bispecific ADC in tumors expressing both antigens but not in tumors expressing only pCAD or only CDH17. Overall, the preclinical data presented here support the proof-of-concept bispecific antibody discovery approach, demonstrating a rational design for screening antibodies by prioritizing cross-arm avid IgGs to target dual-positive cells.

News (Medical) associated with Telisotuzumab vedotin

14 Jan 2026

·www.biospace.com

JPM26: AbbVie Seeks Respect for Oncology Pipeline Following RemeGen Buy

iStock, vzphotos Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P. Morgan presentation: its oncology portfolio is underappreciated. This week, the Illinois-based company dove into the sizzling PD-1/VEGF space with a licensing deal with China-based RemeGen. It’s a poorly kept secret in biopharma that AbbVie intends to become the leading neuroscience company in the near future. It was a point the Illinois-based behemoth reiterated during its J.P. Morgan presentation on Wednesday. “We anticipate being the largest neuroscience player in the industry soon,” Scott Reents, the company’s chief financial officer, said during the presentation. But this wasn’t the only point the company wanted to highlight. “And then the oncology pipeline is something we’re also very excited about that probably isn’t as appreciated as we’d like it to be,” Reents said. AbbVie took significant strides earlier this week to drive this point home, kicking off JPM26 with a licensing deal potentially worth nearly $5 billion for ex-China rights to RemeGen’s PD-1/VEGF bispecific. The pact—which will see AbbVie front $650 million—puts the company squarely in the middle of the hottest new trend in immuno-oncology, on which peers Bristol Myers Squibb, Pfizer and Merck have collectively bet more than $20 billion biobucks. “We feel that can be a very nice complement to our c-MET franchise,” Reents said. AbbVie’s Emrelis, a c-Met-directed antibody and microtubule inhibitor conjugate, was approved by the FDA last May for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression. When asked about AbbVie’s overall approach to oncology R&D, Roopal Thakkar, executive vice president of research & development and chief scientific officer, said the company has “a very strong pipeline internally in a very active research group. . . . So we get assets out of that, a fairly consistent stream.” Indeed, AbbVie currently has 18 investigational drugs in various stages of clinical development listed in its pipeline. However, pointing to the RemeGen deal, Thakkar said, “I think you could anticipate from us looking externally for ways to complement the ADC franchise and on the [hematology] side as well.” The RemeGen pact is far from the only oncology deal AbbVie has inked in recent months. Earlier this month, the company committed more than $1 billion in milestones for the ex-China rights to a Phase III DLL3xDLL3 T cell engager from Suzhou Zelgen Biopharmaceuticals that could challenge Amgen’s Imdelltra. And heading into JPM, AbbVie was one of two companies rumored to be interested in buying Revolution Medicines and its pipeline of targeted drugs for RAS-driven cancers. AbbVie has since denied the rumor. While AbbVie is a well-diversified company with a significant presence in oncology and neuroscience, as well as eye care and aesthetics, it is possibly best known for its success in the immunology space, and the company’s executives spent half the presentation discussing its megablockbusters. Now three years past the Humira loss of exclusivity cliff, AbbVie provided 2027 guidance of $31 billion inclusively for successor products Skyrizi ($20 billion) and Rinvoq ($11 billion). AbbVie plans to provide 2026 guidance for the two drugs when it presents its full-year 2025 earnings on Feb. 4. Reents expressed confidence in the immunology duo’s revenue potential throughout the next several years. “The runway is really significant still through the end of the decade and even into the 2030s as we go forward,” he said. “And that’s based on a certain way these immunology markets are structured and the breadth and depth that we have with both of those assets.”

License out/inPhase 3Drug Approval

20 Nov 2025

·pharma.economictimes.indiatimes.com

US FDA approves Bayer drug for specific type of lung cancer

Bengaluru: The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung cancer that has advanced or spread despite earlier treatments. The drug, branded as Hyrnuo, is approved for non-squamous non-small cell lung cancer (NSCLC) in patients with mutations affecting the HER2 protein, which plays a crucial role in regulating cell growth and development, as identified by an FDA-approved test. Bayer's oral drug belongs to a class of drugs known as kinase inhibitors, which block the action of protein kinases that regulate cell growth. The monthly list price for Hyrnuo is $24,000. Approval of Bayer's drug also heats up competition with privately held Boehringer Ingelheim's Hernexeos, another kinase inhibitor, approved in August for a challenging form of lung cancer. Hyrnuo's approval "provides a welcome addition to the treatment space," said Bayer executive Chandrasekhar Goda. In studies, 71% of the 70 patients who received Hyrnuo, after previous cancer treatments but not those targeting the HER2 mutation, saw their tumors shrink or disappear. In another group of 52 patients who had prior systemic therapy, including HER2-targeting treatments, Bayer's drug helped shrink tumors in 38% of them. NSCLC is the most common type of lung cancer, with about 80% to 85% of all cases. Antibody-drug conjugates such as AbbVie's Emrelis are also approved for a type of NSCLC. The class of therapies acts as "guided missiles" that target only cancer cells while sparing healthy cells, unlike conventional chemotherapy. Other treatment options for NSCLC include Merck's blockbuster Keytruda and AstraZeneca's Tagrisso. FDA also approved the Life Technologies Corporation's test as a companion diagnostic device to help detect the mutations in patients who may be eligible for Bayer's drug. (Reporting by Sriparna Roy in Bengaluru; Editing by Alan Barona, Vijay Kishore and Sherry Jacob-Phillips)>

Drug ApprovalADCClinical Result

13 Oct 2025

·www.prnewswire.com

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie's growing ADC portfolio designed to target difficult-to-treat cancers. NORTH CHICAGO, Ill., Oct. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will unveil new data from its robust antibody-drug conjugate (ADC) platform at the 2025 European Society for Medical Oncology (ESMO) Congress, taking place October 17-21, in Berlin, Germany. Data from investigational and approved ADCs across AbbVie's portfolio such as telisotuzumab adizutecan (Temab-A),1-3 ABBV-706,4,5 and Emrelis™ (telisotuzumab vedotin),6 in patients with difficult-to-treat tumor types where there is urgent need for additional treatment options,7-15 will be featured in multiple presentations. "Despite recent progress in the treatment of advanced solid tumors, patients still face limited options and pressing unmet needs," said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. "The compelling data we are sharing at ESMO showcases how we are advancing targeted therapies across a range of solid tumors and highlights the potential of our portfolio." Key highlights AbbVie will present three oral presentations for Temab-A, a next-generation, investigational c-Met directed ADC with a novel topoisomerase 1 inhibitor (Top1i) payload. Phase 1 results with Temab-A both as a monotherapy and in combination across advanced, solid tumors will be presented: Combination with bevacizumab (Bev) in Colorectal Cancer (CRC): In biomarker unselected patients with advanced CRC who have received three or more prior lines of therapy (NCT05029882), treatment with 2.4 mg/kg dose of Temab-A plus Bev (n=30) achieved an objective response rate (ORR) of 26.7% compared to an ORR of 0% with trifluridine/tipiracil with Bev (the current standard of care (SOC), n = 20).1 Grade ≥3 treatment emergent adverse events (TEAEs) occurred in 67% and 65% of patients, respectively.1 Monotherapy in MET-Amplified Solid Tumors: Among 100 patients with advanced MET-amplified solid tumors, including non-small cell lung cancer (NSCLC) (n=29), CRC (n=22), gastroesophageal adenocarcinoma (GEA) (n=14), and 16 other tumor types (n=35) who had progressed after SOC treatment (NCT05029882), Temab-A monotherapy achieved an ORR of 46% across all dose levels and tumor types with higher responses observed in patients with NSCLC (69%) and GEA (71%).2 The most common grade ≥3 TEAEs were anemia (40%) and neutropenia (34%).2 Monotherapy in Pancreatic Ductal Adenocarcinoma (PDAC ): Among 42 biomarker unselected patients with advanced/metastatic PDAC who experienced disease progression while receiving or after completing their first-line (1L) therapy (NCT06084481), Temab-A demonstrated an ORR of 24% overall and 40% in patients who received first-line gemcitabine-nab-paclitaxel treatment.3 Grade ≥3 TEAEs occurring in ≥10% of all patients were anemia (38%) and neutropenia (21%).3 "Temab-A continues to show meaningful clinical activity across an expanding range of solid tumors and patient populations, including patients with MET-amplification and increased c-Met expression as we have seen in previously presented data," said Vivek Subbiah, M.D., Chief, Early-Phase Drug Development, Sarah Cannon Research Institute and Temab-A investigator. "These data reinforce Temab-A's potential in multiple solid tumors and thereby warrant its further clinical investigation." AbbVie will also present new analysis from a Phase 1 study of ABBV-706, a SEZ6-directed ADC with a Top1i payload, in relapsed/refractory small cell lung cancer (R/R SCLC) (NCT05599984). A post hoc analysis on data from R/R SCLC patients enrolled in the study, whose tumors had progressed after two lines of therapy (n=80), was done to compare the anti-cancer effect of ABBV-706 monotherapy vs. platinum-based SOC. All patients in this group had received the platinum-based SOC treatment as first-line therapy (1L SOC). Progression-free survival (PFS) during 1L SOC and PFS with ABBV-706 monotherapy as a subsequent line of treatment were analyzed in the same patients by paired Kaplan-Meier analysis. The findings suggest that ABBV-706 may have the potential to replace the platinum-based SOC as a first-line treatment in SCLC.4 In the same trial, ABBV-706 treatment also resulted in rapid clearance of circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). Patients with 100% ctDNA clearance had significantly higher PFS and overall survival (OS) vs. patients without ctDNA clearance.5 These data highlight the potential of ctDNA as an early response marker in SCLC.5 A Phase 2 study assessing ABBV-706 in combination with atezolizumab as replacement of platinum-based chemotherapy is currently ongoing (NCT07155174) in 1L SCLC. Details on key presentations at the ESMO 2025 Congress are available below and the full abstracts are available via the ESMO online program. Telisotuzumab adizutecan (Temab-A) and ABBV-706 are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies. Elahere™ (mirvetuximab soravtansine) and Emrelis™ (telisotuzumab vedotin) are approved medicines being investigated for additional uses. Safety and efficacy have not been established for these unapproved additional uses. Additional information on AbbVie clinical trials is available at . U.S. Prescribing Information for AbbVie Medicines Please see full Prescribing information for ELAHERE™ (mirvetuximab soravtansine-gynx) Please see full Prescribing Information for EMRELIS™ (telisotuzumab vedotin-tllv) About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on LinkedIn,Facebook, Instagram, X (formerly Twitter) and YouTube. About AbbVie in Oncology AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines. Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit . Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. References: Cecchini M, Cruz-Correa M, Han SW, et al. Telisotuzumab Adizutecan (ABBV-400; Temab-A) in Combination With Bevacizumab (Bev) in Patients (Pts) With 3+ Colorectal Cancer (CRC): Dose Expansion Results of a Phase 1 Study. Abstract 731MO presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany. Murciano-Goroff YR, Kuboki Y, Strickler J, et al. Telisotuzumab Adizutecan (ABBV-400; Temab-A) in Patients With MET-Amplified Advanced Solid Tumors: Results From a Phase 1 Study. Abstract 918O presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany. Harding JJ, Strickler J, Henry J, et al. Phase 1 Basket Study of Telisotuzumab Adizutecan (Temab-A), a c-Met Protein-Targeting Antibody-Drug Conjugate (ADC): Results from Patients (Pts) With Pancreatic Ductal Adenocarcinoma (PDAC). Abstract 2214MO presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany. Bar J, Dowlati A, Byers LA, et al. Efficacy of ABBV-706 as second-line treatment for patients with platinum-refractory/resistant small cell lung cancer. Abstract 2777P presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany. Wang S, Wang L, Luo A, et al. ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with relapsed/refractory (R/R) small cell lung cancer (SCLC): Circulating biomarker and molecular response analyses. Abstract 2778P presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany. Mansfield AS, Goldman J, Lee SH, et al. Treatment outcomes in patients (pts) with advanced c-Met overexpressing (OE) EGFR wildtype (WT) nonsquamous (NSQ) NSCLC who had telisotuzumab vedotin (Teliso-V) dose modifications in the LUMINOSITY trial. Abstract 1948P presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany. Cassim S, Chepulis L, Keenan R. et al. Patient and carer perceived barriers to early presentation and diagnosis of lung cancer: a systematic review. BMC Cancer. 2019; 19, 25. doi:10.1186/s12885-018-5169-9 Shalata W, Naamneh R, Najjar W, et al. Current and Emerging Therapeutic Strategies for Limited- and Extensive-Stage Small-Cell Lung Cancer. Med Sci. 2025; 13(3):142. doi:10.3390/medsci13030142 Daamen LA, Molenaar IQ, and Groot VP. Recent Advances and Future Challenges in Pancreatic Cancer Care: Early Detection, Liquid Biopsies, Precision Medicine and Artificial Intelligence. J Clin Med. 2023; 12(23):7485. doi:10.3390/jcm12237485 Cereda V and D'Andrea MR. Pancreatic cancer: failures and hopes—a review of new promising treatment approaches. Explor Target Antitumor Ther. 2025;6:1002299. doi: 10.37349/etat.2025.1002299 Deboever N, Jones CM, Yamashita K, et al. Advances in diagnosis and management of cancer of the esophagus. BMJ. 2024; 385 :e074962 doi:10.1136/bmj-2023-074962 Huang J. Overcoming Therapeutic Barriers in Esophageal Cancer Management. J Cancer Clin Trials. 2025;10,289. doi:10.37421/2577-0535.2025.9.289. Nishimuni M, Claro LCL, and Braghiroli MFM. Advancements and challenges in gastric cancer: epidemiology, biomarkers, and therapeutic strategies. Surg Exp Pathol. 2024;7,19. doi.10.1186/s42047-024-00162-4 Li H, Shen M and Wang S. Current therapies and progress in the treatment of advanced gastric cancer. Front Oncol. 2024; 4:1327055. doi:10.3389/fonc.2024.1327055 Pathak PS, Chan G, Deming DA, et al.State-of-the-art management of colorectal cancer: Treatment advances and innovation. Am Soc Clin Oncol Educ Book, 2024; 44(3), p.e438466. doi:10.1200/EDBK_438466 SOURCE AbbVie WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 1ADCPhase 2ASCO

100 Deals associated with Telisotuzumab vedotin

External Link

KEGG	Wiki	ATC	Drug Bank
D11344	-	-	DB15104

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
c-Met positive non-squamous non-small cell lung cancer	United States	AbbVie, Inc.	14 May 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma	Phase 3	-	AbbVie, Inc.	31 May 2024
Non-squamous non-small cell lung cancer	Phase 3	Japan	AbbVie, Inc.	02 Jan 2022
Non-squamous non-small cell lung cancer	Phase 3	Argentina	AbbVie, Inc.	02 Jan 2022
Non-squamous non-small cell lung cancer	Phase 3	Australia	AbbVie, Inc.	02 Jan 2022
Non-squamous non-small cell lung cancer	Phase 3	Austria	AbbVie, Inc.	02 Jan 2022
Non-squamous non-small cell lung cancer	Phase 3	Belgium	AbbVie, Inc.	02 Jan 2022
Non-squamous non-small cell lung cancer	Phase 3	Brazil	AbbVie, Inc.	02 Jan 2022
Non-squamous non-small cell lung cancer	Phase 3	Bulgaria	AbbVie, Inc.	02 Jan 2022
Non-squamous non-small cell lung cancer	Phase 3	Canada	AbbVie, Inc.	02 Jan 2022
Non-squamous non-small cell lung cancer	Phase 3	Chile	AbbVie, Inc.	02 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05513703 (CTgov)	Phase 2	Metastatic Non-Squamous Non-Small Cell Lung Carcinoma \| c-Met positive non-squamous non-small cell lung cancer	9	Telisotuzumab Vedotin	boeuzbjfkk = vhocryfejl jcnysxpuzm (zmpxqoupxq, kglwemxygo - dniwoloulr) View more	-	24 Oct 2025
NCT03539536 (LUMINOSITY, ESMO2025)	Phase 2	c-Met positive non-squamous non-small cell lung cancer c-Met protein overexpression	168	Teliso-V (pts with c-Met protein OE)	apciawvbvr(ablaxpkozf) = xghjnckytm ashavzwils (csjhesyyrg, 17.5 - 41.4)	Positive	17 Oct 2025
				Teliso-V (pts with c-Met high)	apciawvbvr(ablaxpkozf) = tjrzxvjfxb ashavzwils (csjhesyyrg, 18.7 - 46.3)
NCT03539536 (LUMINOSITY, WCLC2025)	Phase 2	squamous cell lung carcinoma Third line \| Second line MET overexpression	168	Telisotuzumab Vedotin 1.9 mg/kg (c-Met OE Total；No PN ≥3)	uqwfmnvgnu(lmykyaqjum) = xjmcospsze uaomikbdlu (qvlgwshgyc ) View more	Positive	08 Sep 2025
				Telisotuzumab Vedotin 1.9 mg/kg (c-Met OE Total；PN ≥3)	uqwfmnvgnu(lmykyaqjum) = xdesizlddv uaomikbdlu (qvlgwshgyc ) View more
NCT03539536 (LUMINOSITY, ASCO2025)	Phase 2	c-Met positive non-small cell lung cancer Second line c-Met overexpression \| KRAS \| BRAF ... View more	83	Teliso-V 1.9 mg/kg	gruxyvasmi(eabtpcpuzk) = vmmgdqslgr aujqfzpkib (ouiqbjlylp ) View more	Positive	30 May 2025
				Placebo	hjdewijeom(tkfmdyutgz) = kvqhijwomv gafqvhwaev (lijvaarnpy ) View more
NCT03539536 (LUMINOSITY, FDA_CDER) Manual	Phase 2	c-Met positive non-small cell lung cancer MET Overexpression	84	EMRELIS (high c-Met protein overexpression)	pgyqjlvamk(tbranzpdyh) = qrttogrbgm hnbuiphrsv (rkqfqiqcef, 24 - 46) View more	Positive	14 May 2025
NCT03539536 (LUMINOSITY, ESMO_ELCC2025) Manual	Phase 2	c-Met positive non-small cell lung cancer \| Advanced Lung Non-Small Cell Carcinoma EGFR Gene Mutation Negative \| MET Overexpression	172	Telisotuzumab vedotin 1.9 mg/kg (c-Met high: ≥50% 3+)	zhjwsgbazk(nthegxnnub) = fjbtfgbzsk pgknkpaqwc (pxzmrvcana, 24.5 - 45.7) View more	Positive	26 Mar 2025
				Telisotuzumab vedotin 1.9 mg/kg (c-Met intermediate [int]: 25 to <50% 3+)	zhjwsgbazk(nthegxnnub) = bnaidygvqt pgknkpaqwc (pxzmrvcana, 15.2 - 34.3) View more
NCT02099058 (Pubmed \| Ann Oncol) Manual	Phase 1	Non-Small Cell Lung Cancer Second line EGFR Mutation \| MET Overexpression	38	Telisotuzumab vedotin + osimertinib	iittfkowqu(xscphvtlkt) = peripheral sensory neuropathy (50%), peripheral edema (32%), and nausea (24%) ocvankbcmw (yjogwgzxit ) View more	Positive	01 Jan 2025
NCT03539536 (ESMO2024)	Phase 2	c-Met positive non-squamous non-small cell lung cancer	-	Telisotuzumab vedotin	glnrzmvftk(iiykoknqmr) = mejihcadmc axahxiffii (rriitlqapr )	-	14 Sep 2024
				Placebo	glnrzmvftk(iiykoknqmr) = bouxmzdmjl axahxiffii (rriitlqapr )
NCT02099058 (WCLC2024) Manual	Phase 1	c-Met positive non-small cell lung cancer MET Overexpression	30	Teliso-v (c-Met-positive tumor cells with 3+ intensity)	fuhnaxkoeh(womrusokzk) = slovxrsjjl fzpnllupwb (lnvhllqosk )	Positive	09 Sep 2024
				Teliso-v (below (A cutoff value of 25% c-Met-positive tumor cells with 3+ intensity))	fuhnaxkoeh(womrusokzk) = zoftkfxpqs fzpnllupwb (lnvhllqosk )
NCT03539536 (LUMINOSITY, Pubmed) Manual	Phase 2	c-Met positive non-small cell lung cancer c-Met protein-overexpressing	172	Telisotuzumab vedotin (Teliso-V)	rrbrneaoip(tfhpitcypk) = wlpnqkmedp cuvunflziu (ovbcdynyaw, 21.7 - 36.2) View more	Positive	06 Jun 2024
				Telisotuzumab vedotin (c-Met high)	rrbrneaoip(tfhpitcypk) = lwqxsgojiw cuvunflziu (ovbcdynyaw, 24.2 - 46.2) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis